A mutation of the human IT15 gene is responsible for Huntington's disease (HD) and the causative factor in the major neuronal loss observed in the striatum. The growth factors basic fibroblast growth factor (FGF-2), nerve growth factor (NGF), and brain-derived neurotrophic factor (BDNF) improve survival and promote differentiation of striatal neurons, as well as exert a neuroprotective effect when such neurons are challenged with metabolic toxins or excitatory amino acids. Using Western blotting and striatal cell cultures, we found that FGF-2 increased the level of huntingtin in a dose-dependent fashion, whereas NGF decreased huntingtin expression. The neurotrophic factor-specific, dose-dependent effect on striatal levels of huntingtin may be relevant to understanding the normal role of IT15 and developing new therapies against the disease pro voking mutated IT15.
INTRODUCTION
Huntington's disease (HD) is an autosomal-dominant genetic neurological disorder caused by a mutation of the IT15 gene, located on chromosome 4 (23) . In the disease-creating form of the gene, a fully translated CAG triplet repeat expansion of the large (348 kDa) IT15 protein (huntingtin) somehow causes the major neuropathology of HD, characterized by striatal atrophy following loss of neurons and a relative sparing of affer ent axons and axons of passage in this anatomical re gion. Excitotoxic or metabolic stress lesions in animal models can closely mimic the neuropathology of HD, indicating that such conditions could participate in the cell death observed (21) . Several different approaches for neurotrophic factor delivery, including immortalized cell lines transfected with a particular neurotrophin (9, 10, 20) , direct application of the recombinant protein (18) , and encapsulated cells (5, 6) , have been used suc cessfully to protect striatal neurons against metabolic or glutamate-mediated toxicity. The exact mechanism of protection remains uncertain, though it is thought to in volve reduced apoptosis and also stabilization of cal cium homeostasis within the cell (8, 12, 25) . This hypoth esis is supported by results showing that the elevation of intracellular calcium levels induced by excitotoxic in sults in cultured hippocampal, cortical, and septal neu rons is reduced by basic fibroblast growth factor (FGF-2), nerve growth factor (NGF), and brain-derived neuro trophic factor (BDNF) treatment (2, 3) .
It has recently been shown that the expansion of the polyglutamine tract (CAG coded) in the huntingtin pro tein results in the formation of neuronal intranuclear in clusions that may underlie the neurological dysfunction observed in mice transgenic for the HD mutation (4).
Also, it has been reported that huntingtin is upregulated after intrastriatal injections of the excitotoxin, quinolinic acid, in rodents and macaques (22) . The functions of both normal and mutant huntingtin, however, remain un clear. Given that the growth factors NGF (9, 20) , FGF-2 (7, 18) , and BDNF (17) have all been shown to protect striatal neurons from excitotoxic injury, it is pertinent to investigate the biological response of the normal HD protein after exposure to these molecules. Using primary murine striatal cultures of the embryonic lateral gangli onic eminence, we report that treatment with these growth factors had a direct effect on the level of hunt ingtin expression in striatal cells.
MATERIALS AND METHODS
For primary striatal cultures, the lateral ganglionic eminences (19) from approximately 12 Sprague-Dawley rat embryos (gestational age El5) were combined and dissociated following incubation in 0.025% trypsin solu tion (37°C, 15 min; Sigma) and trituration in a solution of DNAase (0.01%; Sigma) and trypsin inhibitor (0.05%; Sigma). Isolated cells were collected by centrif ugation and resuspended in Dulbecco's minimum essen tial medium (DMEM; GIBCO, Grand Island, NY) con taining heat-inactivated horse serum (10%), glucose (6 mg/ml), penicillin (10.000 U/ml), streptomycin (10 mg/ ml; Sigma), and glutamine (2 mM; GIBCO). Two milli liters of the suspension at 2.0 x 10 6 cells/ml was plated onto 18-mm polylysine-coated (Sigma) coverslips in wells containing 1 ml of serum containing culture me dium (six-well plates; Falcon). Unattached cells were as pirated after 1 h, and 1 ml of fresh serum-containing medium was added. At 1 day in vitro (DIV), the medium was removed and replaced with defined serum-free cul ture medium (DMEM containing glucose, penicillin, streptomycin, glutamine) and a modified N 2 cocktail (5 mg/ml insulin, 10 mg/ml transferrin, 20 nM progester one, 0.18 mM putrescine, and 20 nM selenium salt) (GIBCO). The neurotrophic factors (R&D Systems, Minneapolis, MN) were used at various concentrations: 5, 10, 50 and 100 ng/ml were diluted in the serum-free culture medium and added to the cells at 1 DIV. The cells were harvested at 2 DIV after 24-h exposure to the neurotrophins. After one rinse of ice-cold phosphatebuffered saline (PBS), the cells were mechanically scraped off the bottom of the well in 50 pi of cell lysis buffer (1 M Tris, pH 8.0, 5 M NaCl, 10% NaAzide, 20% Triton X-100, 10% SDS, 2.2 mg/ml aprotinin, 1.74 mg/ ml PMSF). The cells were kept on ice for 20 min and centrifuged at 12,000 x g for 2 min before being pro cessed for the BioRad protein assay. Protein (20 pg per lane) was loaded onto a 6% polyacrylamide gel and electrophoresis was performed according to standard protocols. The blots were exposed to an anti-IT15 anti body (Chemicon, USA) and visualized using the ECL, chemiluminescence kit from Amersham. An internal standard with a band present at 350 kDa was run on every gel. Each gel also had a treatment control (no trophic fac tor added) that served as a specific comparison for indi vidual Western blot experiments and cell cultures (see bands labeled CONTROL adjacent to a neurotrophic fac tor treatment in Fig. 2 ). The density of the bands was quantified using the specific computer package NIH Im age (Version 1.6.1) for densitometry and those data were later statistically analyzed using one-way analysis of vari ance and regression (JMP; Macintosh).
Some primary embryonic striatal cell cultures were fixed with 4% paraformaldehyde, washed in PBS, and then processed for IT15 (Chemicon) and DARPP-32 (Chemicon) immunohistochemistry. Cells were pre treated with 50% methanol and 0.3% hydrogen peroxide in PBS for 20 min, rinsed three times in PBS, and then preincubated for 1 h in 10% normal blocking serum NBS [NBS: normal goat serum (NGS) in PBS]. The cells were incubated overnight with the primary anti body at a 1:1200 dilution in PBS containing 1% normal goat serum, 1 % bovine serum albumin, and 0.1 % Triton X-100. Cells were then washed with PBS and incubated with goat anti-rabbit biotinylated secondary antibody (Vector Labs) diluted 1:200 in 2% NBS for 90 min, rinsed once in PBS and twice in 0.05 M Tris-buffered saline (TBS). They were then developed with 0.04% hy drogen peroxide and 0.05% 3,3'-diaminobenzidine (Sigma) in TBS for 0-5 min. The coverslips were al lowed to air dry, dehydrated in graded alcohols, cleared in xylene, and finally mounted onto subbed slides.
RESULTS
Striatal neurons were identified using immunohisto chemistry for dopamine-and cyclic AMP-regulated phosphoprotein (DARPP-32). The cultured cells were almost exclusively DARPP-32 positive after 4 days in vitro and they also expressed the IT 15 protein, hunting- LGE cells after 2 days in vitro and one growth factor treatment. Doses written after growth factor treatment in ng/ml (e.g., FGF100 = 100 ng/ml treatment). tin ( Fig. 1 ). To determine if growth factor treatment had mitogenic effects on the cultures or induced glial prolif eration, the plated cells were counted after 4 days in vitro and one treatment of growth factor. There was no difference in the number of neurons in the neurotrophintreated cultures (mean = 120 ± 33) [ To assess and quantify the effects of growth factor treatment on striatal huntingtin levels, protein was ex tracted from the cell cultures and Western blotting was performed (Fig. 2) . Our results show that treatment of striatal cells with FGF-2 increased the level of huntingtin linearly (p < 0.001) in a dose-dependent fashion; at the highest dose administered, 100 ng/ml, FGF-2 caused a dramatic increase in huntingtin expression compared to untreated controls (Table 1) . Neurotrophin treatments with BDNF did not cause any statistically significant effect in this relatively small sample, although average values had a bimodal distribution where at 10 and 50 ng/ml were lower than controls and at 100 ng/ml were above controls. By contrast, the levels of NGF treatment were on average lower on both 10 and 50 ng/ml and resulted in a substantial and statistically significant de crease (p < 0.05) in IT15 expression at 100 ng/ml (Table   1 ) compared to controls. All Western blots were run in duplicate to ensure reliability of the observed effect. Ap propriate controls were run for each specific gel (see Fig. 2 . adjacent lane to neurotrophic factor concentration indicated).
DISCUSSION
Our results indicate that exposure of striatal cells to (9, 20) . There is much evidence to suggest that HD in 
CONCLUSION
The DARPP-32-expressing medium-sized spiny neu rons of the human striatum are particularly vulnerable to the mutation of the huntingtin protein that causes HD.
Using primary murine striatal neuronal cultures, we found that treatment with FGF-2 increased the level of huntingtin linearly. By contrast, high levels of NGF re sulted in reduced IT 15 protein expression. Given that the growth factors NGF and FGF-2 have also been shown to modify cellular injury responses of adult stria tal neurons, their effects on huntingtin expression may be relevant to prevention of neuronal death in HD.
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